Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Jeremy S. Abramson, M.D.

Co-Author

This page shows the publications co-authored by Jeremy Abramson and Jacob Soumerai.
Connection Strength

2.133
  1. Phase 1 study of lenalidomide, bendamustine, and rituximab in previously untreated patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2019 12; 60(12):2931-2938.
    View in: PubMed
    Score: 0.850
  2. Diagnosis and management of Castleman disease. Cancer Control. 2014 Oct; 21(4):266-78.
    View in: PubMed
    Score: 0.618
  3. Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease. Leuk Lymphoma. 2014 Mar; 55(3):538-43.
    View in: PubMed
    Score: 0.569
  4. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood. 2019 05 16; 133(20):2212-2221.
    View in: PubMed
    Score: 0.052
  5. The immunophenotypic spectrum of primary mediastinal large B-cell lymphoma reveals prognostic biomarkers associated with outcome. Am J Hematol. 2016 10; 91(10):E436-41.
    View in: PubMed
    Score: 0.044
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.